Literature DB >> 9795803

Prognostic scores and design of clinical studies.

C Ohmann1.   

Abstract

Randomized controlled clinical trials are the preferred scientific method and remain the vital bridge between basic science and improvements in health care according to general agreement. However, discussion has revealed various critical issues in the field of intraabdominal infection. Many of these critical points can be dealt with by prognostic scoring systems. In this paper the application areas for scores in clinical trials on intraabdominal infections are presented. These areas cover: assessment of severity of disease, definition of inclusion/exclusion criteria, analysis of comparability, adjustment for noncomparability, definition of end points and comparison of observed versus predicted outcome. The use of scoring systems in defining treatment policies is still experimental.

Entities:  

Mesh:

Year:  1998        PMID: 9795803     DOI: 10.1007/bf02962268

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  11 in total

1.  Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections.

Authors:  J S Solomkin; E P Dellinger; N V Christou; R W Busuttil
Journal:  Ann Surg       Date:  1990-11       Impact factor: 12.969

2.  A controlled trial in intensive care units of selective decontamination of the digestive tract with nonabsorbable antibiotics. The French Study Group on Selective Decontamination of the Digestive Tract.

Authors:  H Gastinne; M Wolff; F Delatour; F Faurisson; S Chevret
Journal:  N Engl J Med       Date:  1992-02-27       Impact factor: 91.245

3.  Prognostic modelling in peritonitis. Peritonitis Study Group of the Surgical Infection Society Europe.

Authors:  C Ohmann; Q Yang; T Hau; H Wacha
Journal:  Eur J Surg       Date:  1997-01

4.  Clinical trials from the Surgeon's View.

Authors:  O H Beahrs
Journal:  Cancer       Date:  1990-05-15       Impact factor: 6.860

5.  Randomized controlled clinical trials: The behavioral case.

Authors:  D H Spodick
Journal:  JAMA       Date:  1982-04-23       Impact factor: 56.272

Review 6.  Proposed definitions for diagnosis, severity scoring, stratification, and outcome for trials on intraabdominal infection. Joint Working Party of SIS North America and Europe.

Authors:  P O Nyström; R Bax; E P Dellinger; L Dominioni; W A Knaus; J L Meakins; C Ohmann; J S Solomkin; H Wacha; D H Wittmann
Journal:  World J Surg       Date:  1990 Mar-Apr       Impact factor: 3.352

7.  Etappenlavage: advanced diffuse peritonitis managed by planned multiple laparotomies utilizing zippers, slide fastener, and Velcro analogue for temporary abdominal closure.

Authors:  D H Wittmann; C Aprahamian; J M Bergstein
Journal:  World J Surg       Date:  1990 Mar-Apr       Impact factor: 3.352

Review 8.  Prognostic indices in peritonitis.

Authors:  C Ohmann; T Hau
Journal:  Hepatogastroenterology       Date:  1997 Jul-Aug

9.  Ciprofloxacin vs. cefotaxime regimens for the treatment of intra-abdominal infections.

Authors:  J A Hoogkamp-Korstanje
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

10.  Planned relaparotomy vs relaparotomy on demand in the treatment of intra-abdominal infections. The Peritonitis Study Group of the Surgical Infection Society-Europe.

Authors:  T Hau; C Ohmann; A Wolmershäuser; H Wacha; Q Yang
Journal:  Arch Surg       Date:  1995-11
View more
  3 in total

1.  Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs.

Authors:  Miriam C J M Sturkenboom; Wim G Goettsch; Gino Picelli; Bas in 't Veld; Don D Yin; Romy B de Jong; Peter M N Y H Go; Ron M C Herings
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

Review 2.  Clinical predictors of ongoing infection in secondary peritonitis: systematic review.

Authors:  Bas Lamme; Cecilia W Mahler; Oddeke van Ruler; Dirk J Gouma; Johannes B Reitsma; Marja A Boermeester
Journal:  World J Surg       Date:  2006-12       Impact factor: 3.352

3.  Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.

Authors:  Nathalie Goemans; Marleen Vanden Hauwe; James Signorovitch; Elyse Swallow; Jinlin Song
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.